SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to record October delivery numbers, marking a significant year-over-year increase that has the community buzzing with excitement. Investors are optimistic about NIO's growing ecosystem and potential for further expansion, particularly with its innovative battery-swapping technology. Community members are closely watching for continued growth and a potential turning point towards profitability.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members highlight its strong ties to the Bitcoin network and its fair launch distribution. Discussion points include its potential for mainstream adoption and comparisons to other memecoins. The community emphasizes its organic growth and increasing recognition within the crypto space.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid speculation about a potential short squeeze and renewed interest in privacy coins. Some community members are drawing comparisons to Bitcoin's early days, while others highlight its limited supply and upcoming halving event. The conversation includes discussion of potential price targets and whether ZEC can outperform other cryptocurrencies.

Bounce Token

Bounce Token is trending as traders discuss its potential for significant gains, fueled by its relatively low supply and active development. Community members are pointing to its history of massive pumps, with some anticipating a run to previous highs. The conversation includes speculation on potential price targets and comparison to other low-cap coins.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending amid discussions about its potential role in powering AI data centers, particularly with its natural gas-fueled fuel cell technology. The community is analyzing the ExxonMobil conference call and its implications for FCEL's carbon capture technology, while comparing it to sector peers like Bloom Energy. High trading volume and options activity further fuel the stock's increased attention.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is trending due to concerns around declining deliveries and increased competition in the Chinese EV market, highlighted by a recent drop in stock price and lowered Q3 guidance. Community discussions revolve around the impact of these factors on the company's future profitability and market share, especially compared to competitors like XPeng and NIO. Investors are also weighing potential catalysts, including the upcoming launch of the i6 model and long-term growth prospects.

Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.

Medical Properties Trust Inc

MPW is trending as investors weigh mixed Q3 results, including year-over-year revenue growth offset by higher interest expenses and a miss on NFFO per share estimates. The community is actively debating the stock's profitability, potential for a short squeeze given high short interest, and the impact of ongoing restructuring efforts and a recently announced share buyback program. Bullish investors point to equity value exceeding share price and potential for positive EPS, while bears express concerns about rising interest expenses and struggling tenants.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter (JUP) is trending as community members express bullish sentiment and analyze charts for potential double bottoms. There's also significant discussion around the meme coin $UPDOG, which is listed on Jupiter, with users highlighting its community and potential for becoming a millionaire. Additionally, Jupiter Lend and its features like high LTVs are being discussed.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending amid analyst upgrades and anticipation for upcoming earnings, with the community eyeing potential AI-related announcements. Bullish sentiment seems to be building as the stock approaches 52-week highs, while some traders debate the company's valuation. Chatter surrounds a possible acquisition of GitLab which could have impacts in the software space.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor ($TAO) is gaining attention due to its role in decentralized AI, positioning itself as a competitor to centralized AI developers. Community members are focused on its upcoming halving event and potential institutional investment via an ETP. The community is also actively discussing staking yields and subnet developments within the Bittensor network.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of +180.00% and -1.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +100.00% and +2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of CytomX Therapeutics hit their highest levels in nearly two months on Monday after the company&nbsp;posted better-than-expected first-quarter earnings and revealed promising early trial results for its lead oncology candidate.CytomX posted quarterly earnings per share of $0.27, which surpassed analyst estimates of $0.13.&nbsp;Its revenue climbed to $50.92 million, also beating analyst estimates of $35.42 million.CytomX shares surged by 129.4% on Monday, reaching $2.13.The company revealed early Phase 1 trial results showing positive outcomes for CX-2051, an EpCAM-directed Probody antibody-drug conjugate targeting late-line colorectal cancer (CRC).The CTMX-2051-101 Phase 1 study provided these results after beginning the trial in April 2024.&nbsp;The clinical research on April 7 included 25 patients with metastatic CRC who received CX-2051 treatment through seven different dose levels during three-week intervals.Among the 18 patients receiving therapeutic doses of the CX-2051 treatment, 28% reached confirmed partial response according to RECIST v1.1 standards, which surpasses the standard response rates of low to mid-single digits associated with third-line or later colorectal cancer treatments.&nbsp;Patients on CX-2051 received 10 mg/kg, where three out of seven achieved confirmed partial responses.&nbsp;The Disease Control Rate (DCR) reached 94% across these doses while the median progression-free survival stood at 5.8 months.&nbsp;Ten patients stayed on study treatment at the point of data cutoff out of 18 participants.CEO Sean McCarthy, D.Phil., expressed his optimism about the results while confirming that CX-2051 continues to be the company's number one strategic focus.&nbsp;McCarthy said that the findings establish EpCAM as a valuable target in cancer treatment and enable CX-2051 to advance into CRC applications and various other EpCAM-expressing cancer types.The current dose expansion phase will lead CytomX to start a Phase 2 study in early 2026.Additionally, CytomX priced its 76.9 million share secondary offering at $1.30 per share.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,567% increase in 24-hour message volume.One user expressed confidence that the stock could reach $3.50 the following day.&nbsp;<stembedurl>https://stocktwits.com/LittleWhiteBall/message/614390932</stembedurl>Another noted the rarity of a stock rising after a company issues a secondary offering at a significantly lower price.<stembedurl>https://stocktwits.com/engrman1/message/614387241</stembedurl>The stock has risen 100.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CytomX Stock Hits 2-Month High After Upbeat Q1 Earnings, Promising Early Data For Cancer Drug

The company shared Phase 1 trial results for CX-2051, an antibody-drug conjugate for advanced colorectal cancer, with 28% of patients achieving confirmed partial responses.

Equity

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates

Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates PR Newswire...

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection PR Newswire VANCOUVER, BC, May...

Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed...

What's Going On With CytomX Stock?

CytomX Therapeutics shares are racing higher Wednesday. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8, after the close...

HC Wainwright Comments on CytomX Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ:CTMX  Free Report)  Research analysts at HC Wainwright issued their FY2025 EPS estimates for CytomX Therapeutics in a report released on Monday...

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the...

CytomX Therapeutics announces milestone achievement in PROBODY TCB

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CTMX
CytomX Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CTMX News

CTMXCytomX Therapeutics Inc